BioSpace News Archive

Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Immunology (ACAAI).

Here are some tips for excellent science communication, as well as resources for good communication skills. Applying these in life will make a huge change.

To answer the question of whether biotech is truly keeping up with diversity and inclusion today, the complicated answer is the movement is “ still in progress.”

AstraZeneca is significantly expanding its footprint in China with the establishment of a global research and development center in the country, as well as the launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.

Under the new deal, Artios Pharma licensed rights to research, develop, manufacture and commercialize products globally from a small-molecule ATR inhibitor program that was jointly developed by MD Anderson and ShangPharma.

Takeda will unload a portfolio of over-the-counter and prescription pharmaceutical products to Germany-based STADA for $660 million as the company continues to pare down debt from its $62 billion acquisition of Shire.

The recent announcement of CRISPR Prime, a novel version of the system, addresses the targeting problem and brings CRISPR-based therapy one step closer to reality.

Artios Pharma Limited, The University of Texas MD Anderson Cancer Center and ShangPharma Innovation announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.

It’s fascinating to see things moving in an entirely new direction thanks to the work of these seven millennial biotech influencers.

Reaffirms Biocon’s Capability to Manufacture Biosimilars for Patients in U.S.